Impala Asset Management LLC Acquires New Shares in Precigen, Inc. $PGEN

Posted by Brenda Bartman on Jun 14th, 2026

Impala Asset Management LLC acquired a new stake in shares of Precigen, Inc. (NASDAQ:PGEN – Free Report) in the fourth quarter, Holdings Channel reports. The fund acquired 165,000 shares of the biotechnology company’s stock, valued at approximately $690,000. Precigen accounts for 0.4% of Impala Asset Management LLC’s investment portfolio, making the stock its 21st biggest holding.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Barclays PLC boosted its position in Precigen by 55.7% during the 4th quarter. Barclays PLC now owns 865,378 shares of the biotechnology company’s stock valued at $3,617,000 after purchasing an additional 309,522 shares during the period. The Manufacturers Life Insurance Company boosted its position in Precigen by 10.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 5,222 shares during the period. CANADA LIFE ASSURANCE Co acquired a new position in Precigen during the 4th quarter valued at approximately $85,000. Stifel Financial Corp boosted its position in Precigen by 8.8% during the 4th quarter. Stifel Financial Corp now owns 82,657 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 6,700 shares during the period. Finally, Rafferty Asset Management LLC boosted its position in Precigen by 264.3% during the 4th quarter. Rafferty Asset Management LLC now owns 374,202 shares of the biotechnology company’s stock valued at $1,564,000 after purchasing an additional 271,478 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PGEN shares. Citigroup restated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, HC Wainwright lifted their target price on Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.50.

View Our Latest Report on PGEN

Insider Activity at Precigen

In other news, CFO Harry Jr. Thomasian sold 41,884 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $182,614.24. Following the sale, the chief financial officer directly owned 554,535 shares of the company’s stock, valued at $2,417,772.60. The trade was a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Rutul R. Shah sold 42,703 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $186,185.08. Following the sale, the chief operating officer directly owned 497,751 shares in the company, valued at $2,170,194.36. This trade represents a 7.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,005,749 shares of company stock valued at $16,765,918 over the last ninety days. Company insiders own 47.10% of the company’s stock.

Precigen Stock Down 1.8%

Shares of Precigen stock opened at $4.45 on Friday. The stock’s fifty day moving average is $4.12 and its 200-day moving average is $4.07. The firm has a market capitalization of $1.59 billion, a PE ratio of -3.77 and a beta of 1.06. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. Precigen, Inc. has a 12-month low of $1.38 and a 12-month high of $5.47.

Precigen (NASDAQ:PGEN – Get Free Report) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. Equities analysts anticipate that Precigen, Inc. will post -0.02 earnings per share for the current year.

About Precigen

(Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.